[The synergistic action of lipopolysaccharide and muramyl dipeptide in the immunotherapy of DBA/2 mice with mastocytoma P815].
The intratumoral administration of lipopolysaccharide (LPS) and muramyl dipeptide (MDP) in combination, but not separately, resulted in necrosis and rejection of subcutaneous P815 mastocytoma nodules in DBA/2 mice with 30 to 40% survival. Previous sensibilization of animals by LPS + MDP, treatment by indomethacin, cyclophosphamide or syngeneic lymphocytes did not augment the immunotherapeutic action of LPS + MDP combination. Reinoculation of P815 cells into cured DBA/2 mice 8 months after the disappearance of the primary tumor led to rejection of new nodules with 50% survival rate. In LPS + MDP immunotherapy of these tumors two stages may be distinguished by a thrombo-necrotic stage and that of development of immunity.
Rakhmilevich
A L
AL
Rakhimova
M S
MS
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000627:therapeutic use*; D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D007167:Immunotherapy / Q000379:methods*; D007213:Indomethacin / Q000627:therapeutic use; D008070:Lipopolysaccharides / Q000627:therapeutic use*; D008297:Male; D012515:Mast-Cell Sarcoma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D012074:Remission Induction; D013997:Time Factors
D008070:Lipopolysaccharides; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D003520:Cyclophosphamide; D007213:Indomethacin
Sinergichnoe deĭstvie lipopolisakharida i muramildipeptida pri immunoterapii mysheĭ DBA/2 s mastotsitomoĭ P815.